1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag

SynAct Participating at Redeye Autoimmune and Inflammatory Diseases event on November 19th

SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, announced that the company will present at Redeye’s Autoimmune and Inflammatory Diseases event in Stockholm on November 19th at 14:05 CET.

SynAct’s Chief Business Officer Mads Bjerregaard will present the latest on lead compound resomelagon, a potential first-in-class, non-suppressive immune system modulator, and the potential use in treatments for rheumatoid arthritis and acute inflammation due to viral infections.

“I’m excited to join peers from Swedish biotech at the Redeye event presenting our innovations in the field of immunology,” said Mads Bjerregaard, CSO at SynAct. “We believe that resomelagon is a novel approach to help patients overcome inflammatory disorder and we are excited to share our updates with investors in this important field of medicine.”

To view the presentation online use the following link:
https://www.redeye.se/events/1112314/redeye-theme-autoimmune-and-inflammatory-diseases-2

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/.

Attachments
SynAct Participating at Redeye Autoimmune and Inflammatory Diseases event on November 19th

Datum 2025-11-19, kl 07:30
Källa MFN
Bifogade filer
SynAct Participating at Redeye Autoimmune and Inflammatory Diseases event on November 19th
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!